Summit Therapeutics (SMMT) Total Non-Current Liabilities (2018 - 2026)

Summit Therapeutics (SMMT) has reported Total Non-Current Liabilities for 9 consecutive years, with $120.4 million the latest figure, recorded in Q2 2026.

• Quarterly Total Non-Current Liabilities rose 91.84% year-over-year to $120.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $120.4 million (up 91.84% YoY) and the FY2025 annual result came in at $90.5 million, up 100.28% from the prior year.
• Total Non-Current Liabilities advanced to $120.4 million in Q2 2026 per SMMT's latest filing, from $100.1 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for SMMT reached as high as $536.1 million in Q4 2022 and fell as low as $19.7 million in Q3 2022.
• A 5-year average of $110.4 million and a median of $95.3 million in 2025 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities surged 1862.67% — and 2023, when it plunged 76.93%.
• Year by year, Total Non-Current Liabilities stood at $536.1 million in 2022, then tumbled by 76.93% to $123.7 million in 2023, then plunged by 63.47% to $45.2 million in 2024, then jumped by 100.28% to $90.5 million in 2025, then jumped by 33.05% to $120.4 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $120.4 million, $100.1 million, and $90.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.